Vor Biopharma Inc (VOR)

Form 8-K - Current report

Vor Bio Appoints David Zaccardelli to Board of Directors

BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company...

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 8-K - Current report

Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China

First regulatory approval for Sjögren’s disease (SjD) First and only approved therapy for SjD in China...

Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China

First and only approved BAFF/APRIL-targeting therapy for IgA nephropathy (IgAN)  Approval based on positive...

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology...

Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference

BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients...

Form EFFECT - Notice of Effectiveness

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]